204 related articles for article (PubMed ID: 38424468)
1. Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate.
Kawakatsu R; Tadagaki K; Yamasaki K; Yoshida T
Sci Rep; 2024 Feb; 14(1):4975. PubMed ID: 38424468
[TBL] [Abstract][Full Text] [Related]
2. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
3. Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia.
Knight T; Edwards H; Taub JW; Ge Y
Cancer Manag Res; 2019; 11():3197-3213. PubMed ID: 31118772
[TBL] [Abstract][Full Text] [Related]
4. Oridonin Synergistically Enhances the Pro-Apoptotic Effect of Venetoclax on Acute Myeloid Leukemia Cells by Inhibiting AKT Signaling.
Chen L; Li D; Guo X; Cheng C; Wei X
Front Biosci (Landmark Ed); 2023 Sep; 28(9):195. PubMed ID: 37796705
[TBL] [Abstract][Full Text] [Related]
5. Maximal Activation of Apoptosis Signaling by Cotargeting Antiapoptotic Proteins in BH3 Mimetic-Resistant AML and AML Stem Cells.
Carter BZ; Mak PY; Tao W; Zhang Q; Ruvolo V; Kuruvilla VM; Wang X; Mak DH; Battula VL; Konopleva M; Jabbour EJ; Hughes PE; Chen X; Morrow PK; Andreeff M
Mol Cancer Ther; 2022 Jun; 21(6):879-889. PubMed ID: 35364607
[TBL] [Abstract][Full Text] [Related]
6. A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells.
Zhao T; He Q; Xie S; Zhan H; Jiang C; Lin S; Liu F; Wang C; Chen G; Zeng H
Mol Med; 2023 Jan; 29(1):10. PubMed ID: 36658493
[TBL] [Abstract][Full Text] [Related]
7. Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist Venetoclax.
Satta T; Li L; Chalasani SL; Hu X; Nkwocha J; Sharma K; Kmieciak M; Rahmani M; Zhou L; Grant S
Clin Cancer Res; 2023 Apr; 29(7):1332-1343. PubMed ID: 36652560
[TBL] [Abstract][Full Text] [Related]
8. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.
Rahmani M; Nkwocha J; Hawkins E; Pei X; Parker RE; Kmieciak M; Leverson JD; Sampath D; Ferreira-Gonzalez A; Grant S
Cancer Res; 2018 Jun; 78(11):3075-3086. PubMed ID: 29559471
[TBL] [Abstract][Full Text] [Related]
9. Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation.
Liu F; Kalpage HA; Wang D; Edwards H; Hüttemann M; Ma J; Su Y; Carter J; Li X; Polin L; Kushner J; Dzinic SH; White K; Wang G; Taub JW; Ge Y
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32847115
[TBL] [Abstract][Full Text] [Related]
10. Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies.
Zhai Y; Tang Q; Fang DD; Deng J; Zhang K; Wang Q; Yin Y; Fu C; Xue SL; Li N; Zhou F; Yang D
Clin Cancer Res; 2023 Jan; 29(1):183-196. PubMed ID: 36240005
[TBL] [Abstract][Full Text] [Related]
11. Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner.
Huang S; Li C; Zhang X; Pan J; Li F; Lv Y; Huang J; Ling Q; Ye W; Mao S; Huang X; Jin J
Mol Oncol; 2020 Oct; 14(10):2560-2573. PubMed ID: 32519423
[TBL] [Abstract][Full Text] [Related]
12. Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance.
Liu F; Zhao Q; Su Y; Lv J; Gai Y; Liu S; Lin H; Wang Y; Wang G
Exp Hematol; 2022 Jan; 105():39-49. PubMed ID: 34767916
[TBL] [Abstract][Full Text] [Related]
13. 8-Cl-Ado and 8-NH
Guo J; Buettner R; Du L; Li Z; Liu W; Su R; Chen Z; Che Y; Zhang Y; Ma R; Nguyen LXT; Moore RE; Khyatiben P; Chen MH; Patrick P; Wu X; Marcucci G; Wang L; Horne D; Chen J; Yang Y; Rosen ST
Leukemia; 2024 Jun; 38(6):1236-1245. PubMed ID: 38643304
[TBL] [Abstract][Full Text] [Related]
14. Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms.
Yuan F; Li D; Li G; Cheng C; Wei X
Ann Transl Med; 2022 Apr; 10(8):490. PubMed ID: 35571387
[TBL] [Abstract][Full Text] [Related]
15. DRP1 Inhibition Enhances Venetoclax-Induced Mitochondrial Apoptosis in TP53-Mutated Acute Myeloid Leukemia Cells through BAX/BAK Activation.
Jang JE; Hwang DY; Eom JI; Cheong JW; Jeung HK; Cho H; Chung H; Kim JS; Min YH
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765703
[TBL] [Abstract][Full Text] [Related]
16. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N
Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848
[TBL] [Abstract][Full Text] [Related]
17. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.
Ewald L; Dittmann J; Vogler M; Fulda S
Cell Death Dis; 2019 Dec; 10(12):917. PubMed ID: 31801941
[TBL] [Abstract][Full Text] [Related]
18. Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax.
Gaur T; Poddutoori R; Khare L; Bagal B; Rashmi S; Patkar N; Tembhare P; Pg S; Shetty D; Dutt A; Zhang Q; Konopleva M; Platzbeckar U; Gupta S; Samajdar S; Ramchandra M; Khattry N; Hasan SK
J Exp Clin Cancer Res; 2023 Jul; 42(1):186. PubMed ID: 37507802
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effect of chidamide and venetoclax on apoptosis in acute myeloid leukemia cells and its mechanism.
Li G; Li D; Yuan F; Cheng C; Chen L; Wei X
Ann Transl Med; 2021 Oct; 9(20):1575. PubMed ID: 34790781
[TBL] [Abstract][Full Text] [Related]
20. Hymeglusin Enhances the Pro-Apoptotic Effects of Venetoclax in Acute Myeloid Leukemia.
Zhou C; Wang Z; Yang S; Li H; Zhao L
Front Oncol; 2022; 12():864430. PubMed ID: 35847946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]